Skip to content
Biosion
  • About
    • Executive Team
    • Development Team
    • Advisory Board
    • Careers
  • Platform
    • H3 Antibody Technology
    • SynTracer™ Internalization Platform
    • FlexibodyTM Bispecific Platform
  • Pipeline
  • Partners
  • News
  • Contact
  • English
  • 中文
  • About
    • Executive Team
    • Development Team
    • Advisory Board
    • Careers
  • Platform
    • H3 Antibody Technology
    • SynTracer™ Internalization Platform
    • FlexibodyTM Bispecific Platform
  • Pipeline
  • Partners
  • News
  • Contact
  • English
  • 中文

Careers

Join Our Team and Grow With Us

At Biosion, we are innovators, leaders, and collaborators. We love what we do and who we work with. And at the heart of everything we do is an intense desire to innovate for cures and to improve quality of life.

Job opportunities

SynTracer™ Internalization Platform

The SynTracer™ Antibody Discovery Platform enables identification of antibodies with efficient internalization rates, providing promising candidates for Antibody Drug Conjugates (ADCs).

  The SynTracer™ platform allows for:

  • High-throughput endocytosis screening to identify the best internalizing antibodies
  • Plug & play conjugation with a fixed DAR=2 to facilitate robust and efficient screening
  • Simulation of ADC processes & MOA with high sensitivity, efficiency, and productivity

SynTracerTM Antibody Discovery Platform  is able to identify the lead candidate with highest endocytosis activity, thus providing a foundation of best-in-class ADC development

Key challenges and opportunities of ADC generation

  • Most current ADC-antibodies not from endocytosis screening
  • The higher endocytosis activity of antibody, the higher bioactivity of ADC
  • The breakthrough and the big success of DS8201 highlights a hugh opportunity for next generation of ADC development

Key features

  • IgG auto-conjugating-toxin: no cell binding & endocytosis activity
  • A plug-&-play IgG auto-conjugation method – DAR=2
  • Simultaneously mimicking ADC endocytosis & killing process
  • High sensitivity due to directly cytotoxicity

Key applications

  • Candidates with high endocytosis activity: ADC generation

Technical validation: Internal validation completed and patent filed in 2021

Committed to bring next generation innovative therapeutics to treat immune and oncologic diseases.

LinkedIn

CHINA

BIOSION, INC.

5th Floor, Building D
3-1 Zhongdan Unit
South Longshan Rd
Jiangbei New District
Nanjing, Jiangsu, China 210061
Tel: (86) 025-5829-1977

USA

BIOSION USA, INC.

1 Innovation Way, Suite 300
Newark, DE 19711
Tel: 1-302-998-5126

Australia

BIOSION AUSTRALIA PTY LTD.

58 Gipps Street
Collingwood, Victoria 3066
Tel: 1-302-998-5126

Website by Bartlett Interactive
Terms Privacy
© 2022. All rights reserved.
Close Bitnami banner
Bitnami